Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Invetech and Biocartis Announce Biomarker Collaboration

Published: Wednesday, April 16, 2014
Last Updated: Wednesday, April 16, 2014
Bookmark and Share
Agreement supporting global development and manufacture of instrument to analyze protein and nucleic acid biomarkers continues multi-year relationship.

Invetech and Biocartis announced a collaboration agreement to support development and manufacture of Evalution™, Biocartis’ advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers.

The EvalutionTM platform, designed to support a range of applications in the clinical research and pharmaceutical markets, provides an integrated reaction and detection environment and supports simultaneous analysis of large numbers of analytes per assay. The technology offers real-time visualization of the reaction and data traceability for easy and reliable assay development.

“We first established a collaborative agreement with Biocartis in 2008 when they were a relatively small startup company. Since that time, our team has delivered the full range of our product realization expertise to support their rapid growth and expansion, from project initiation right through to manufacturing. In addition to our instrument development services we have provided Biocartis with guidance in areas including regulatory, sustaining engineering and instrument service. We look forward to continuing our relationship to help them advance and maximize the potential of the EvalutionTM platform in the years ahead,” said David James, Senior Vice President Diagnostics of Invetech.

EvalutionTM is engineered to reduce hands-on time and development complexity, with the potential to streamline procedures for biomarker verification and validation. Currently, Biocartis has multiple scientific collaborations and partnerships in place for the development of novel content on the EvalutionTM platform, targeting development of assays in the fields of oncology, cardiology, neurology, and immunology.

“At every stage in our growth, and our focus on product development and manufacturing, our relationship with Invetech has been marked by a high level of collaboration as well as outstanding responsiveness, ease of communication, and flexibility. We look forward to their contributions to the production and expansion of the EvalutionTMplatform and our efforts to improve data quality, speed to results, and cost-effectiveness in bioassays around the world,” said Paul Ladestein, Managing Director Business Unit Evalution, Biocartis.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biocartis to Present BRAF Liquid Biopsy Data at ASCO Annual Meeting
BRAF mutations identified by Idylla™ from circulating tumor DNA in plasma associated with treatment response.
Thursday, June 04, 2015
Biocartis and Fast-track Diagnostics Sign Strategic Collaboration
Both Companies aim to develop a range of multiplex tests on the Biocartis Idylla™ system each detecting a range of infectious disease pathogens.
Wednesday, May 27, 2015
Biocartis And Microbiome Collaborate
Collaboration aims to develop rapid and sensitive sepsis test.
Thursday, April 09, 2015
Biocartis Spins Out Life Sciences Multiplex Platform Evalution into Mycartis
Company has combined its Swiss Evalution business unit with Pronota NV to form MyCartis.
Saturday, September 06, 2014
Biocartis Raises EUR 64.5 Million
Investment supports commercial roll-out of Idylla™, Biocartis’ flagship molecular diagnostics system, and the development of the system’s menu of diagnostics tests.
Friday, September 05, 2014
Biocartis and VIB Join Forces
Company will develop a new CRC assay for MSI biomarker detection.
Monday, December 09, 2013
Biocartis Announces the End of its Alliance with bioMérieux
Agreement for the development and commercialization of the integrated molecular biology system, Idylla™.
Friday, November 29, 2013
Biocartis Announces Completion of EUR 30 Million Series E Equity Fundraising
Company poised for 2014 commercial launch.
Thursday, November 07, 2013
Biocartis and Hospital del Mar Join Forces
License agreement to develop diagnostic colon cancer test.
Monday, October 21, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos